As for the role in glioma treatment of immune checkpoint PD-1 and CTLA-4 targeting drugs, for a long time we believed that such drugs could not be used in brain cancer because of the impossibility of reaching glioma cells and microenvironment [73]. This evidence concerns the gene PDCD1 and glioma.